Benzamil (Benzylamiloride), an Amiloride analogue, is a Na⁺/Ca²⁺ exchanger (NCX) inhibitor (IC₅₀~100 nM). Benzamil also is a non-selective Deg/epithelial sodium channels (ENaC) blocker, and can potentiate myogenic vasoconstriction. Benzamil inhibits TRPP3-mediated Ca²⁺-activated currents, with an IC₅₀ of 1.1 μM^[1][2][3]. In Vitro: Benzamil (Benzylamiloride) inhibits neuronal and heterologously expressed small conductance Ca²⁺-activated K²⁺ channels^[4]. In Vivo: Benzamil (Benzylamiloride) (0.7 mg/kg/day; s.c.) treated stroke-prone spontaneously hypertensive rats (SHRSP) survived, on average, until 16.1 weeks of age in SHRSP rats^[5].